HLB Life Science Q1 2026: Operating Loss Continues, Rivoceranib NDA Resubmission Completed, No Shareholder Returns

Q1 2026 consolidated revenue: 15.2 billion KRW (up 61% YoY)
Operating loss: 6.5 billion KRW (loss widened from 5.7 billion)
Net loss: 7.8 billion KRW (sharply narrowed from 57.2 billion due to lower financial asset impairment)
Debt ratio: 60.05% (increase from 56.11% at year-end 2025)
NDA for Rivoceranib (liver cancer 1st line) resubmitted to FDA in February 2026
Pyrotinib Phase 3 trials for breast/lung cancer ongoing; hemostatic agent BleeFix under regulatory review
Issued 15.7 billion won in 16th exchangeable bonds; provided 49.6 billion won in guarantees for subsidiaries
No share buybacks, cancellations, or dividends
Lawsuit against NH Investment & Securities for 7.5 billion won pending at Supreme Court